|Page (1) of 1 - 08/11/17||email article||print page|
(August 11, 2017)
- New MRG-106 Phase 1 cutaneous T-cell lymphoma clinical trial data released
- Expansion of the MRG-106 trial to include additional potential indications
- Two new independent members added to its Board of Directors
- Conference call and webcast today at 4:30 p.m. ET
BOULDER, Colo., Aug. 11, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced second quarter 2017 financial results and provided a corporate update.
?The second quarter of 2017 has been marked by a number of important development milestones as we position the company for additional clinical opportunities, said miRagen President and Chief Executive Officer, William S. Marshall, Ph.D. ?In addition to reporting positive new interim Phase 1 clinical trial data underscoring our belief in the potential of the MRG-106 program, we completed our MRG-201 Phase 1 clinical trial and established a potential path forward for expanding both development programs into additional indications. The results generated in both clinical trials represent significant strides forward in execution of our foothold clinical development strategy. We believe that the continued application of the foothold clinical approach may allow us to expand opportunities for our microRNA targeted therapeutic candidates in the future.
Business Highlights and Update
- Reported new interim MRG-106 Phase 1 clinical trial results, and announced plans to expand the program to include additional potential indications: New interim results from the Companys ongoing Phase 1 clinical trial of MRG-106 in subjects with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2017. Eighteen of nineteen subjects (95%), independent of administration route, showed improvement in either the individual lesion or total skin disease as measured by maximal change in either Composite Assessment of Index Lesion Severity or modified Severity Weighted Assessment Tool (mSWAT), respectively.
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter
Source:Copyright (c) GlobeNewswire, Inc. All Rights Reserved